Chief of Thoracic Surgery
Weill Cornell Medicine
Dr. Nasser K. Altorki is the Chief of the Division of Thoracic Surgery at the NY-Presbyterian Hospital and is the David B. Skinner Professor of Cardiothoracic Surgery at Weill Cornell Medical College. Leader of the Experimental Therapeutics Program at the Sandra and Edward Meyer Cancer Center and Director of the Neuberger Berman Lung Cancer Research Center. He completed his surgical and cardiothoracic training at the University of Chicago and joined the faculty at WCM in 1988. Professional interests include: the surgical treatment of esophageal and lung cancer, minimally invasive surgical techniques, and clinical trials in lung and esophageal cancer. Beyond his expertise in the surgical treatment of lung cancer and other chest malignancies, he has a longstanding interest in studying the immune landscape as well as immunotherapy for early stage lung cancer and has led several trials of adjuvant and neoadjuvant immunotherapy in early stage lung cancer. Has served as the principle investigator on a number of national and international clinical trials, and has written numerous manuscripts and book chapters on lung cancer screening, staging and management of early lung cancer.Dr. Altorki established the Neuberger Berman Lung Cancer Research Program at WCM to support laboratory -based translational lung cancer research. The program’s primary objective is to explore the role of the tumor immune microenvironment in the initiation and progression of lung cancer. Over the years this program has matured and expanded to include four principal investigators. He is also a member of numerous professional organizations, including the IASLC, the American Society of Clinical Oncology, the American Association for Thoracic Surgery, the Society of Thoracic Surgeons, the American College of Surgeons, and the American Association of Cancer Research. Last, but not least, Dr. Altorki is a passionate patient advocate and thoughtful teacher and mentor to many residents, fellows, and junior faculty.
Angiocrine Bioscience: Stockholder; Astra Zeneca: Research Advisory Committee; TMRW: Stockholder; View Point Medical: Stockholder
Sunday, January 30, 2022
1:00 PM – 2:00 PM ET